JSKN033 in Chinese Subjects with Advanced Malignant Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

430

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Advanced Malignant Tumors

Interventions

DRUG

JSKN033

JSKN033 should be administered subcutaneously on the first day of each week cycle/ each 2-week cycle

All Listed Sponsors

lead

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

INDUSTRY